Amundi Sells 71,482 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Amundi decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,154,826 shares of the medical equipment provider’s stock after selling 71,482 shares during the quarter. Amundi owned about 0.58% of Zimmer Biomet worth $117,261,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC raised its holdings in Zimmer Biomet by 2.3% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock worth $485,000 after purchasing an additional 102 shares during the last quarter. Larson Financial Group LLC raised its holdings in Zimmer Biomet by 10.6% during the 4th quarter. Larson Financial Group LLC now owns 3,769 shares of the medical equipment provider’s stock worth $398,000 after purchasing an additional 362 shares during the last quarter. Generali Investments CEE investicni spolecnost a.s. bought a new position in Zimmer Biomet during the 4th quarter worth approximately $644,000. AMG National Trust Bank bought a new position in Zimmer Biomet during the 4th quarter worth approximately $3,697,000. Finally, Ashton Thomas Private Wealth LLC grew its position in shares of Zimmer Biomet by 106.7% during the 4th quarter. Ashton Thomas Private Wealth LLC now owns 9,062 shares of the medical equipment provider’s stock worth $959,000 after buying an additional 4,678 shares during the period. Institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Raymond James reduced their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Finally, Truist Financial reaffirmed a “hold” rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $124.15.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.95% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $110.08 on Tuesday. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock’s fifty day simple moving average is $105.65 and its two-hundred day simple moving average is $107.13. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The stock has a market cap of $21.91 billion, a PE ratio of 24.74, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm posted $2.20 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.